The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Botaneco

Monday Biotech Deal Review: February 13, 2012

Welcome to your Monday Biotech Deal Review for February 13, 2012.  There was some interesting biotech activity over the previous two weeks, including the closing by Oncolytics of its $18.5M equity financing and the withdrawal by Valeant of its offer to acquire ISTA Pharmaceuticals and its acquisition of a Brazilian food and sport supplement company.  [...]

Monday Biotech Deal Review: October 17, 2011

Welcome to your Monday Biotech Deal Review for October 17, 2011.  This week’s deal review is a double feature following last Monday’s Canadian thanksgiving holiday.  Of note from the past two weeks were the acquisition of Labopharm by Paladin Labs, and its announcement that it is ceasing its hostile takeover pursuit of Afexa. 

Monday Biotech Deal Review: February 22, 2010

There was a lot of follow-up among Canadian biotech deals this week: letters of intent turning into definitive agreements, merged companies turning to consolidation, bids launched on schedule and wrapped up; as well as an average crop of new M&Eh and securities.  Start things off with an interesting (cross-border!) twist to the SIFT/SR&ED deals we’ve [...]

Monday Biotech Deal Review: November 30, 2009

It was a fairly quiet week last week, but you still have options (har) after the jump, as well as an equity line, a debt settlement, a rights offering, licenses, and deals closing in a reasonably timely manner.

Monday Biotech Deal Review: November 2, 2009

In this week’s Deal Review: SemBioSys hops on the SIFT Tax bandwagon; new deals from Microbix, OPMEDIC and GeneNews; and good updates from iCo Therapeutics, QLT, Noveko and Oncolytics.

Monday Biotech Deal Review: October 25, 2009

A very busy deal week coincided with a very busy work week (for those of us with day jobs), so allow me a particularly grateful thank-you to Jacob Cawker, who’s been an invaluable help with the Deal Review this and the last several weeks.  After the jump, licenses both inbound, outbound and just tied up (optioned); securities extended and [...]

Monday Deal Review: August 3, 2009

Hopefully, the Deal Review will be a longer list as the newly-launched Ontario Emerging Technologies Fund starts deploying some capital, but for this week, the Canadian deal front was pretty quiet.   A few developments, like the JLL-Patheon pathos and the milestone for Cardiome from Merck, were noted at the time in our Twitter stream @crossborderbio, and [...]

Follow

Get every new post delivered to your Inbox.

Join 92 other followers